Doxepin benefits.

uses of Doxepin Doxepin is used to treat mental/mood problems such as depression, anxiety and bipolar disorder. It may help improve mood and feelings of well-being, relieve anxiety and tension, help we sleep better, and increase your energy level. Doxepin belongs to a class of medications called tricyclic antidepressants. It works by affecting balance of certain natural chemicals ( neurotransmitters ) in brain.

how to use of Doxepin Read Medication Guide available from your pharmacist. Consult your doctor or pharmacist if we have any questions.

Take Doxepin by mouth, usually 1 to 3 times daily or as directed by your doctor. If you take it only once a day, take it at bedtime to help reduce daytime sleepiness. The dosage is based on your age, medical condition and response to therapy. Your doctor may start we at a low dose and gradually increase your dose over several weeks. Follow your doctor's instructions carefully.

Use dropper that comes with medication to measure out the prescribed amount. Just before taking, mix drug with half a glass ( 4 ounces or 120 milliliters ) of water, whole/skim milk, or orange, grapefruit, tomato, prune or pineapple juice, and drink all of mixture. Do not mix with soda or other carbonated beverages. If we are taking Doxepin in combination with liquid methadone, we may mix both drugs with lemonade, orange juice, sugar water, orange drink mix, or plain water, but not grape juice. Mix only what we need for each dose. Don't prepare a supply for future use.

Doxepin doesn't work right away. It may take up to 2 to 3 weeks before we experience full benefits.

Use Doxepin regularly in order to get most benefit from it. To help we remember, take it at the same times each day.

It's important to continue taking Doxepin even if we feel well. Do not suddenly stop taking Doxepin without consulting your doctor. Some conditions may become worse when the drug is abruptly stopped. Muscle aches, headaches and worsening anxiety may also occur. Your dose may need to be gradually decreased.

Tell your doctor if your condition persists or worsens.

other used of Doxepin This section contains uses of Doxepin that are not listed in the approved professional labeling for drug but that may be prescribed by your health care professional. Use Doxepin for a condition that's listed in this section only if it has been so prescribed by your health care professional.

If directed by your doctor, Doxepin may also be used to treat certain types of pain ( e. g. , peripheral neuropathy, neuropathic pain ) and trouble sleeping.

side effects of Doxepin See also Warning section.

Drowsiness, dizziness, dry mouth, blurred vision, constipation, fast heartbeat, nausea, vomiting, loss of appetite, changes in taste, weight gain, or trouble urinating may occur while use Doxepin. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.

To relieve dry mouth, suck on ( sugarless ) hard candy or ice chips, chew ( sugarless ) gum, drink water, or use a saliva substitute.

Remember that your doctor has prescribed Doxepin because he or she has judged that benefit to we is greater than the risk of side effects. Many people using Doxepin don't have serious side effects.

Tell your doctor immediately if any of these unlikely but serious side effects occur:

Tell your doctor immediately if any of these rare but very serious side effects occur:

A very serious allergic reaction to Doxepin is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction may include:

This isn't a complete list of possible side effects. If we notice other effects not listed above, contact your doctor or pharmacist.

precautions of Doxepin See also the Warning section.

Before taking Doxepin, tell your doctor or pharmacist if we are allergic to it, or to other tricyclic antidepressants ( e. g. , amitriptyline ) , or if we have any other allergies.

Doxepin should not be used if we have certain medical conditions. Before using this medicine, consult your doctor or pharmacist if we have:

Before using Doxepin, tell your doctor or pharmacist your medical history, especially of:

Doxepin may make you drowsy or dizzy or cause blurred vision; use caution engaging in activities requiring alertness or clear vision such as driving or using machinery. Limit alcoholic beverages.

To minimize dizziness and risk of fainting, get up slowly when rising from a sitting or lying position.

Before having surgery, tell your doctor or dentist that we are taking Doxepin.

Doxepin may make we more sensitive to the sun. Avoid prolonged sun exposure, tanning booths, and sunlamps. Wear sunblock ( SPF 30 or greater ) and a hat when outdoors.

If you have diabetes, Doxepin may increase your blood sugar levels. Check your blood sugar levels regularly as directed by your doctor. Tell your doctor immediately if we have symptoms such as increased thirst/urination, shakiness, unusual sweating, or hunger. Your anti-diabetic medication or diet may need to be adjusted.

Depression can lead to thoughts/attempts of suicide. Tell your doctor immediately if we have any suicidal thoughts, worsening depression, or any other mental/mood changes ( including new or worsening anxiety, agitation, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, rapid speech ) . Keep all medical appointments so your doctor can monitor your progress closely and adjust your medication if needed.

Caution is advised when using Doxepin in the elderly because they may be more sensitive to its side effects, especially dizziness, drowsiness, confusion, and difficulty urinating.

Caution is advised when using Doxepin in children. ( See also Warning section. ) Doxepin should be used only when clearly needed during pregnancy. Discuss risks and benefits with your doctor.

Doxepin passes into breast milk and may have undesirable effects on a nursing infant. Breast-feeding while using Doxepin isn't recommended. Consult your doctor before breast-feeding.

interactions of Doxepin Your healthcare professionals ( e. g. , doctor or pharmacist ) may already be aware of any possible drug interactions and may be monitoring we for it. Don't start, stop or change the dosage of any medicine before checking with them first.

Doxepin shouldn't be used with following medications because very serious ( possibly fatal ) interactions may occur:

Avoid taking MAO inhibitors within 2 weeks before and after treatment with Doxepin. In some cases a serious, possibly fatal drug interaction may occur while use Doxepin.

If we are currently using any of these medications listed above, tell your doctor or pharmacist before starting Doxepin.

Other drugs besides Doxepin that may affect the heart rhythm ( QT prolongation in EKG ) include disopyramide, cisapride, halofantrine, pimozide among others. Before taking Doxepin, report all medications we are currently using to your doctor or pharmacist. QT prolongation can infrequently result in serious ( rarely fatal ) fast/irregular heartbeat and other symptoms ( e. g. , severe dizziness, fainting ) that require immediate medical attention. Ask your doctor or pharmacist for more details and for instructions on how you may reduce risk of this effect.

Before using Doxepin, tell your doctor or pharmacist of all prescription and nonprescription/herbal products we may use, especially of:

If we have been taking fluoxetine, wait at least 5 weeks after stopping fluoxetine before starting Doxepin.

Cigarette smoking decreases blood levels of this medication. Tell your doctor if we smoke or if you have recently stopped smoking.

Tell your doctor or pharmacist if you also take drugs that cause drowsiness such as:

Check labels on all your medicines ( e. g. , cough-and-cold products ) because they may contain drowsiness-causing ingredients. Ask your pharmacist about safe use of those products.

Also report use of drugs which might increase seizure risk ( decrease seizure threshold ) when combined with Doxepin such as bupropion, isoniazid ( INH ) , theophylline, or tramadol, among others. Consult your doctor or pharmacist for details.

This document does not contain all possible interactions. Therefore, before using Doxepin, tell your doctor or pharmacist of all products we use. Keep a list of all your medications with you, and share list with your doctor and pharmacist.

overdose of Doxepin If overdose of Doxepin is suspected, contact your local poison control center or emergency room immediately. US residents can call US national poison hotline at 1-800-222-1222. Canadian residents should call their local poison control center directly. Symptoms of overdose may include: severe dizziness, hallucinations, fast/irregular heartbeat, fainting, widened pupils, muscle stiffness, seizures.

notes of Doxepin Don't share Doxepin with others.

Laboratory and/or medical tests ( e. g. , kidney function, Doxepin blood level ) may be performed from time to time to monitor your progress or check for side effects. Keep all medical appointments. Consult your doctor for more details.

missed dose of Doxepin If you miss a dose Doxepin, take it as soon as you remember. If it is near time of the next dose, skip missed dose and resume your usual dosing schedule. Do not double dose of Doxepin to catch up.

storage of Doxepin Store Doxepin at room temperature between 59-86 degrees F ( 15-30 degrees C ) . Keep away from light and moisture. Do not store Doxepin in bathroom. Keep all medicines away from children and pets.

Properly discard Doxepin when it's expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.

warning of Doxepin Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. These medications can help prevent suicidal thoughts/attempts and provide other important benefits. However, studies have shown that a small number of people ( especially children/teenagers ) who take antidepressants for any condition may experience worsening depression, other mental/mood symptoms, or suicidal thoughts/attempts. Therefore, it's very important to talk with the doctor about risks and benefits of antidepressant medication ( especially for children/teenagers ) , even if treatment is not for a mental/mood condition. Tell doctor immediately if we notice worsening depression/other psychiatric conditions, unusual behavior changes ( including possible suicidal thoughts/attempts ) , or other mental/mood changes ( including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech ) . Be especially watchful for these symptoms when a new antidepressant is started or when dose is changed.

Where to buy Doxepin

First Patients Enrolled In MIV Therapeutics VESTASYNC II Study

MIV Therapeutics, Inc. ( OTCBB: MIVT ) ( Frankfurt: MIV ) , a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announces that first patients have been enrolled in the registration trial of its VESTAsync™ polymer-free drug-eluting stent. Based on excellent nine-month human safety and efficacy data reported in March at American College of Cardiology meeting, Company has accelerated its original timeline for the VESTASYNC II trial, which is designed to test efficacy of VESTAsync™ in a sufficient number of patients to form basis of a regulatory filing for marketing approval in Europe. It's anticipated that these patient data will also be part of an eventual submission to U. S. Food and Drug Administration.

Alexandre Abizaid, M. D. , Ph. D. , Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, is a principal investigator in this 120-patient, multi-center, randomized, controlled study. In this study 90 patients will receive the VESTAsync™ nano-porous hydroxyapatite ( HAp ) coated drug-eluting stent, while 30 patients will receive Company's VESTAcor™ stent, company's nano-porous HAp coated stent, which contains no drug. The primary endpoint is late lumen loss as measured by Quantitative Coronary Angiography ( QCA ) at nine months. Secondary endpoints will include major adverse cardiac events and volumetric obstruction. Intravascular Ultrasound ( IVUS ) , Optical Coherent Tomography ( OCT ) and physiological sub studies are also expected to be performed.

" We're accelerating this registration trial due to results obtained with VESTAsync™ in our pilot study after nine-month patient follow up, and potential to address safety issues in currently marketed drug-eluting stents using polymers to deliver drug, " commented Doctor Mark Landy, president and chief executive officer of MIV Therapeutics. " Our stent is a polymer-free, nanoscale, microporous hydroxyapatite stent that has ability to deliver a much smaller effective dose of drug, in fact 60 percent less, with safety of bare-metal stents, and probably requires only short-term anticoagulant therapy. Currently available drug-eluting stents require patients to take anticoagulants, such as Plavix, for as long as one year. We intend for the data obtained from this study to support an application for CE mark of VESTAsync™ by end of 2009 and are looking forward eventually to offering patients and physicians a superior alternative to currently available products, " Doctor Landy added.

About MIV Therapeutics

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite ( HAp ) , an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on stent market, which have been associated with undesirable effects. The Company's drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with University of British Columbia and has received a government grant for its research program on " Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents, " under National Research Council-Industrial Research Assistance Program. Under this sponsorship, Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV's intellectual property portfolio includes patents held by University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect commercial exclusivity of MIV's inventions in global marketplace. For more information, please visit http: //www. mivtherapeutics. com.

Forward-Looking Statements

Except for historical information contained herein, matters discussed in this press release are forward-looking statements. All statements that discuss expectations and projections with respect to future matters including, without limitation, statements relating to the safety and efficacy of Company's product and the ability of Company's product to rejuvenate stent market are forward-looking statements. Such statements are indicated by words or phrases such as " proposed, " " expected, " " believe, " " will, " " breakthrough, " " significant, " " indicated, " " feel, " " revolutionary, " " should, " " ideal, " " extremely " and " excited. " These statements are made under " Safe Harbor " provisions of Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, market acceptance of Company's product, ability of Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated, and other factors identified in the Company's filings with Securities and Exchange Commission including, without limitation, the Company's annual report on Form 10-K for year ended May 31, 2007 and Forms 10-Q. The Company expressly disclaims any obligation to update publicly or otherwise revise these statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

MIV Therapeutics

Helpful healthcare tips by many topics wait you.

Radiology and Children: Extra Care Required. Image Gently, a campaign launched this year, aims to raise awareness about opportunities to lower the radiation dose during the medical imaging of children.

Vital Facts About HIV Home Test Kits. Many HIV home tests are illegally marketed online and in newspapers and magazines. Consumers should know that there is only one FDA-approved home test system for HIV.

Sentinel System to Monitor Medical Product Safety. FDA's new Sentinel Initiative aims to establish a national electronic system for tracking medical product performance.

Prostate Cancer Treatment Could Impair Men's Thinking. TUESDAY, July 29 -- Men undergoing hormonedeprivation therapy to keep prostate cancer at bay may experience memoryloss and have trouble concentrating, a new study finds.

Thyroid Hormone May Boost Women's Alzheimer's Risk. TUESDAY, July 29 -- High or low levels of thehormone thyrotropin may be associated with an increased risk ofAlzheimer's disease in women. Thyrotropin affects thyroid gland functionand thyroid hormone levels.

Clinical Trials Update: July 29, 2008. -- Here are the latest clinical trials, courtesyof CenterWatch:.

Impotence drugs help treat brain tumors: study. Impotence drugs may help carry cancer-fighting drugs through the brain to treat malignant tumors, U.S. researchers reported on Monday.

Obesity not a contraindication to knee replacement. Obese individuals with arthritic knees should not be denied knee replacement surgery, researchers conclude, based on a new study showing that obese patients benefit from the surgery almost as much as their normal-weight peers.

Children target of $1.6 billion in food ads, FTC finds. Imagine Superman promoting fresh fruits and vegetables instead of a cereal.

Rapid rise seen in fatal medication errors at home. Deaths from medication mistakes at home, like actor Heath Ledgers accidental overdose, rose dramatically during the past two decades, an analysis of U.S. death certificates finds.